Stock FATE FATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
5.27 USD -2.04% Intraday chart for Fate Therapeutics, Inc. -15.95% +40.91%
Mar. 21 Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC CI
Mar. 19 Fate Therapeutics Prices $100 Million Offering, Private Placement MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
GL
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GL
Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC
CI
Fate Therapeutics Prices $100 Million Offering, Private Placement
MT
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
GL
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC
CI
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index
CI
Transcript : Fate Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GL
Fate Therapeutics to Present at Upcoming March Investor Conferences
AQ
Fate Therapeutics to Present at Upcoming March Investor Conferences
GL
Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating
MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating
MT
Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating
MT
Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating
MT
Transcript : Fate Therapeutics, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fate Therapeutics: Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FATE Stock
  4. News Fate Therapeutics, Inc.